Juan A. Gallego, MD, MS

Assistant Investigator, The Feinstein Institute for Medical Research

Assistant Professor of Psychiatry, Hofstra Northwell School of Medicine

Phone: (718) 470-8177
E-mail: jgallego@nshs.edu

About the Investigator

Dr. Gallego is currently an Assistant Professor at Hofstra Northwell School of Medicine and an Assistant Investigator at the Feinstein Institute for Medical Research. Dr. Gallego completed his residency training in psychiatry at SUNY Downstate Medical Center in Brooklyn and a research fellowship at The Zucker Hillside Hospital, the psychiatric hospital for Northwell Health.

Dr. Gallego has a strong background in clinical research. He obtained a master’s degree in clinical research methods at Albert Einstein College of Medicine and has participated as a study physician and co-investigator in various randomized controlled trials with first episode schizophrenia patients. He is currently a co-investigator in a double-blind, randomized, controlled trial comparing adjuvant Omega-3 fatty acids vs. placebo in first episode psychosis patients on treatment with risperidone.

For the past few years, Dr. Gallego adopted a translational approach to his work. His current research focus is on the role of microRNAs in cerebrospinal fluid and peripheral blood in patients with schizophrenia. Additionally, he is conducting a pilot study using induced pluripotent stem cells derived from first episode psychosis patients. He receives grant funding from NIMH (K23 career development award) and the Brain and Behavior Research Foundation (NARSAD Young Investigator award).

Lab Members

Christopher Morell, MA
Research Coordinator
Email: CMorell@NSHS.edu
Phone: (718) 470-8439


Albert Einstein College of Medicine
Degree: MS
Field of Study: Clinical Research Methods

The Zucker Hillside Hospital, Glen Oaks, NY
Field of Study: Research Fellowship

SUNY Downstate Medical Center, Brooklyn, NY
Field of Study: Psychiatry Residency

Universidad CES, Medellín, Colombia
Degree: MD
Field of Study: Medicine

Awards & Honors

2013 Domestic Travel Award Winner. Biological Psychiatry Meeting. San Francisco, US. May 2013.
2012 New Investigator Travel Award. World Congress of Psychiatric Genetics. Hamburg, Germany, 2012.
2011 Travel Award. Critical Research issues in Latino Mental Health Conference. Miami, November, 2011.
2011 Early Career Investigator Program finalist. World Congress of Psychiatric Genetics. Washington DC, September, 2011.
2011 New investigator travel award. “Pharmacogenetics in Psychiatry” meeting. New York, April 2011.
2010 Faculty Development Fellowship. Sponsored by the Bronx CREED center, Albert Einstein College of Medicine. Awarded on May 2010.
2010 Schizophrenia International Research Society Meeting. Florence, Italy. Travel Award.
2009 NCDEU new investigator award program. Hollywood, FL. June 2009.
2009 “APA’s Research Colloquium for Junior Investigators” award. San Francisco, CA. May 2009.
2008 1st place at the 2008 Residents paper competition Brooklyn Psychiatric Society, a branch of the American Psychiatric Association.
2008 “Outstanding Clinical Performance” award at the Residents and Fellows Alumni Society SUNY Downstate Medical Center. Brooklyn, NY.
2008 Award in recognition of “Outstanding Scholastic Performance in Research”. SUNY Downstate Medical Center. June 25th 2008. Brooklyn, NY.
1999 “Manuel Uribe Angel” Award for graduate students.
1999 Academy of Medicine of Medellin. In recognition of the best medical students and interns within the three medical schools at Medellin, Colombia.
1996 Academic Achievement Award for Best Medical Student. Instituto de Ciencias de la Salud, CES. Medellin, Colombia.

  1. Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK. “Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia.” JAMA Psychiatry. 2014 Nov 5;PubMed PMID: 25372846.
  2. Toteja N, Gallego JA, Saito E, Gerhard T, Winterstein A, Olfson M, Correll CU. “Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol.” 2014 Jul;17(7):1095-105. PubMed PMID: 23673334; PubMed Central PMCID: PMC4010557.
  3. Szeszko PR, Robinson DG, Ikuta T, Peters BD, Gallego JA, Kane J, Malhotra AK. “White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology.” 2014 May;39(6):1324-31. PubMed PMID: 24549105; PubMed Central PMCID: PMC3988536.
  4. Ikuta T, Robinson DG, Gallego JA, Peters BD, Gruner P, Kane J, John M, Sevy S, Malhotra AK, Szeszko PR. “Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.” Psychiatry Res. 2014 Feb 28;221(2):127-34. PubMed PMID: 24120303; PubMed Central PMCID: PMC3946302.
  5. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. “Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.” Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18. PubMed PMID: 23199972; PubMed Central PMCID: PMC3594563.
  6. Peters BD, Szeszko PR, Radua J, Ikuta T, Gruner P, DeRosse P, Zhang JP, Giorgio A, Qiu D, Tapert SF, Brauer J, Asato MR, Khong PL, James AC, Gallego JA, Malhotra AK. “White matter development in adolescence: diffusion tensor imaging and meta-analytic results.” Schizophr Bull. 2012 Nov;38(6):1308-17. PubMed PMID: 22499780; PubMed Central PMCID: PMC3494037.
  7. Correll CU, Gallego JA. “Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.” Psychiatr Clin North Am. 2012 Sep;35(3):661-81. PubMed PMID: 22929872; PubMed Central PMCID: PMC3717367.
  8. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. “Safety and tolerability of antipsychotic polypharmacy.” Expert Opin Drug Saf. 2012 Jul;11(4):527-42. PubMed PMID: 22563628; PubMed Central PMCID: PMC3384511.
  9. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. “Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.” Schizophr Res. 2012 Jun;138(1):18-28. PubMed PMID: 22534420; PubMed Central PMCID: PMC3382997.
  10. Gallego JA, Gordon ML, Claycomb K, Bhatt M, Lencz T, Malhotra AK. “In vivo microRNA detection and quantitation in cerebrospinal fluid.” J Mol Neurosci. 2012 Jun;47(2):243-8. PubMed PMID: 22402993; PubMed Central PMCID: PMC3361591.
  11. Ikuta T, Szeszko PR, Gruner P, DeRosse P, Gallego J, Malhotra AK. “Abnormal anterior cingulate cortex activity predicts functional disability in schizophrenia.” Schizophr Res. 2012 May;137(1-3):267-8. PubMed PMID: 22406209; PubMed Central PMCID: PMC3351499.
  12. Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. “Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?” J Clin Psychiatry. 2011 Dec;72(12):1691-6. PubMed PMID: 21939612; PubMed Central PMCID: PMC3246541.
  13. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. “Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.” Schizophr Res. 2011 Sep;131(1-3):58-62. PubMed PMID: 21419603; PubMed Central PMCID: PMC3159758.

View more at PubMed